Lexeo Therapeutics (LXEO) Shares Outstanding (Weighted Average) (2022 - 2026)

Lexeo Therapeutics has disclosed Shares Outstanding (Weighted Average) across 5 years of filings, most recently posting $81.2 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $81.2 million, up 145.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.2 million (up 145.16% YoY), and the FY2025 annual result was $53.6 million, up 68.76% from the prior year.
• Shares Outstanding (Weighted Average) came in at $81.2 million for Q1 2026 at Lexeo Therapeutics, up from $53.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $81.2 million in Q1 2026 to a low of $1.6 million in Q1 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $31.4 million (2024), against an average of $27.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) gained 0.07% in 2023 and jumped 1943.22% in 2024, its largest moves.
• Lexeo Therapeutics' Shares Outstanding (Weighted Average) stood at $1.6 million in 2022, then surged by 228.42% to $5.4 million in 2023, then surged by 493.67% to $31.8 million in 2024, then jumped by 68.76% to $53.6 million in 2025, then soared by 51.33% to $81.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $81.2 million (Q1 2026), $53.6 million (Q4 2025), and $61.0 million (Q3 2025), per Business Quant data.